← Tüm fırsatlar

Horizon Europe · Avrupa Birliği

Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential

Açık

AB Ufuk Avrupa programı tarafından 5 hibe bekleniyor; proje başına €9 milyon – €11 milyon; toplam bütçe €44,2 milyon. Başvurular 17 Şubat 2027 tarihinde kapanıyor (AB çağrıları genellikle Brüksel saatiyle 17:00’de kapanır). AB üye ülkelerindeki ve Türkiye gibi ortak ülkelerdeki kuruluşlar genellikle katılabilir; konu koşulları belirleyicidir.

Resmi açıklamalar fon sağlayıcının dilindedir (çoğunlukla İngilizce); bu sayfadaki özet ve temel bilgiler Türkçedir.

Beklenen sonuçlar

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• The scientific and clinical communities have a better understanding of and access to experimental antivirals for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation.

• Candidate antiviral therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.

Kapsam

Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of antivirals targeting conserved viral or host mechanisms would provide a critical preparedness measure against future health threats caused by (re)emerging infectious disease epidemics or pandemics, due to infectious disease epidemics or pandemics.

This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation of the European Medical Countermeasures Strategy [1] .

Antibodies and antibody derived proteins are excluded from the scope of this topic.

Applicants should explicitly state in their proposal which of the following viruses/groups of viruses is targeted and the proposed work should address only this specific virus/group of viruses. The proposed work should aim to advance the development of novel or existing antiviral candidates targeting exclusively one of the following viruses/groups of viruses:

Kimler başvurabilir

Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).

Başvuru sahibi kategorileri yalnızca bir başlangıç noktasıdır. Uygunluğa resmi çağrı karar verir.

Konular

Clinical development, Phase I Clinical trials Cohort studies Disease control Drug development, clinical phases Emerging Epidemics Epidemiology Infectious diseases Patient safety Preparedness Public health and epidemiology Statistics in clinical trials, Phase I Tick Viruses Andes Enterovirus GMP Hantaan Hendra Junin

Zamanlama

Single-stage call. Next deadline 2027-02-17. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).

Nasıl başvurulur

1. Portaldaki konunun tamamını okuyun: beklenen sonuçlar, kapsam, faaliyet türü ve ülke veya konsorsiyum kısıtlamaları dahil uygunluk koşulları.
2. Kuruluşunuzu AB Funding & Tenders Portalına kaydederek her ortak için bir PIC numarası alın.
3. İşbirliğine dayalı araştırma ve yenilik projeleri genellikle üç farklı AB üye ülkesi veya ortak ülkeden en az üç bağımsız ortak gerektirir (Türkiye Ufuk Avrupa’ya ortak ülkedir). Bu konudaki kuralı doğrulayın.
4. Bölüm A’yı (portalda doldurulan idari formlar ve bütçe) ve Bölüm B’yi (bu faaliyet türü için resmi şablondaki teknik açıklama) hazırlayın.
5. Son başvuru günü kapanış saatinden önce portal üzerinden gönderin. Geç başvurular kabul edilmez.

From the call text

Who can apply

Not stated in the call text we hold — check the official page

Company stage

Not stated in the call text we hold — check the official page

Single applicant or consortium

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Where applicants must be based

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Where to apply

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

AB başvuru rehberini okuyun

Resmi kaynaklar

Resmi çağrı sayfası

Bu sayfadaki bilgiler resmi kaynaktan alınmıştır ve en son 14 Kasım 2026 tarihinde kontrol edilmiştir. Sonraki değişiklikler dahil, fon sağlayıcının kendi belgeleri her zaman önceliklidir.

Horizon Europe: diğer çağrılar